ZYBERNO
Stock Report
Updated Aug 31, 2026

Protara Therapeutics, Inc. (TARA)

Healthcare • NASDAQ

$3.82

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
Protara Therapeutics, Inc. (TARA) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-41.7%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.03x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-52.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Protara Therapeutics, Inc. (TARA) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, TARA generated -$56.46M in Owner Earnings. Capital was deployed as follows: $94.00K invested in capital expenditures. Reinvestment rate: 0.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.82
Market Cap:$233.05M

Valuation Multiples (2)

P/B Ratio:1.44x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$218.72M

Price Action & Momentum (3)

Momentum Percentile:68 / 100
% of 52-Week High:48.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-38.8%
Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-0.2%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$34.60
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-75.6%
Latest Earnings Filed:2026-08-11
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:10.97x
Quick Ratio:10.97x
Cash Ratio:1.28x

Leverage Analysis (3)

Debt To Equity Ttm:0.03x
Debt-to-Equity Ratio:0.03x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-52.52x
Times Interest Earned:-52.52

Capital Structure (4)

Working Capital:132,833,000.00
Cash And Cash Equivalents:17,076,000.00
Long Term Debt:$1.46M
Net Debt:-$14.33M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$76.79M

Bottom Line Performance (3)

-$70.02M
Income Before Tax:$57.35M
Ebitda Ttm:-76,423,000.00

Operating Expenses (5)

Operating Expenses:76,792,000.00
R And D Expense:53,232,000.00
Sga Expense:23,560,000.00
Income Tax Expense:$0.00
Interest Expense:1,229,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$176.09M
Current Assets:$146.15M
Ppe Net:1,318,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:14,782,000.00
Current Liabilities:13,319,000.00
Long Term Debt:$1.46M
Short Term Debt:$1.29M

Equity & Capital (3)

Equity:$161.31M
Retained Earnings:-$341.87M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:4,663,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,384,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$63.00M-$63.09M

Investment Activities (2)

Investing Cash Flow:-$14.72M
Capital Expenditures Ttm:94,000.00

Financing Activities (3)

Financing Cash Flow:$1.14M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:369,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.37
-$1.37
Earnings Per Share Ttm:-$1.15

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.92

Book Value & Capital (2)

Book Value Per Share:$2.64
Cash Per Share:0.28

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$56.46M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-0.2%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):9.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:TARA
Company Name:Protara Therapeutics, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:61.01M
Shares Outstanding Basic:61.01M
Shares Outstanding Diluted:61.01M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 06:46:31 UTC
Data Timestamp:2026-08-18T18:26:57.987471
Scroll to Top